Homology Medicines, Inc.

Q32 Bio, Inc. has found a route to the public markets through a reverse merger with Homology Medicines, Inc. , one of three transactions it announced 16 November as it positions itself as a public c

UroGen Pharma, Ltd. anticipated filing for US Food and Drug Administration approval in 2024 for UGN-102 in the treatment of low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMI

AstraZeneca is to spend around $68m to acquire the beleaguered LogicBio Therapeutics and its gene therapy platform – a generous payout which could provide a template for further deals in the space.

Biopharmaceutical companies continue to reveal restructuring plans and job cuts even as valuations overall are improving, with many second quarter earnings calls revealing a wave of actions aimed at c